LOS ANGELES, June 25 (Reuters) - Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S.

Adagrasib and pembrolizumab combination therapy achieved a median PFS of 27.7 months in KRASG12C-mutated NSCLC patients with PD-L1 ≥50%. The combination therapy showed a 59.3% overall response rate, ...